Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026
Clinical and prognostic implications of (1,3)-beta-D-glucan in adult patients with intra-abdominal candidiasis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Albanell-Fernández Marta, Vergara Andrea, Herrera Sabina, Tuset Montse, Soriano Álex, Bodro Marta
Аннотация
INTRODUCTION: The clinical relevance and prognostic value of serum (1,3)-beta-D-glucan (BDG) in patients with intra-abdominal candidiasis (IAC) remains poorly characterized.
METHODS: We conducted a retrospective single-center study (2020-2025) in adult patients with IAC who had a BDG measurement (Fujifilm Wako β-glucan test) within ±3 days of a positive culture. Demographic, clinical, and microbiological data were collected. Outcomes included end-of-treatment and 30-day mortality, and recurrence. Statistical analyses were performed using STATA, and BDG results stratified patients.
RESULTS: Among 18 IAC patients, BDG showed a sensitivity of 66.6% (95%CI: 41-86.7%). Negative BDG results were associated with a higher prevalence of Nakaseomyces glabratus (57.1% vs. 33.3%), lower end-of-treatment mortality (0% vs. 50%, P=0.05), and shorter ICU stays (median 14.5 vs. 29.5 days, P=0.01) compared with BDG-positive patients.
CONCLUSION: The BDG shows limited sensitivity in IAC. Negative BDG may indicate lower fungal burden and better outcomes. Despite its limitations, BDG may represent a valuable prognostic marker.
METHODS: We conducted a retrospective single-center study (2020-2025) in adult patients with IAC who had a BDG measurement (Fujifilm Wako β-glucan test) within ±3 days of a positive culture. Demographic, clinical, and microbiological data were collected. Outcomes included end-of-treatment and 30-day mortality, and recurrence. Statistical analyses were performed using STATA, and BDG results stratified patients.
RESULTS: Among 18 IAC patients, BDG showed a sensitivity of 66.6% (95%CI: 41-86.7%). Negative BDG results were associated with a higher prevalence of Nakaseomyces glabratus (57.1% vs. 33.3%), lower end-of-treatment mortality (0% vs. 50%, P=0.05), and shorter ICU stays (median 14.5 vs. 29.5 days, P=0.01) compared with BDG-positive patients.
CONCLUSION: The BDG shows limited sensitivity in IAC. Negative BDG may indicate lower fungal burden and better outcomes. Despite its limitations, BDG may represent a valuable prognostic marker.